search button
Open Access

Circulating microRNA‑103a‑3p could be a diagnostic and prognostic biomarker for breast cancer

  • Authors:
    • Hui Liu
    • Qing-Zhao Bian
    • Wei Zhang
    • Hai-Bin Cui

  • View Affiliations

  • Published online on: December 3, 2021     https://doi.org/10.3892/ol.2021.13156
  • Article Number: 38

  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Breast cancer (BC) is the most frequent cancer for women worldwide. Recently, a spectrum of cell‑free circulating microRNAs (miR) has been recognized as promising biomarkers for BC diagnosis and prognosis, among which miR‑103a‑3p has been reported in several types of human cancer. However, the role of miR‑103a‑3p in BC remains unknown. A total of 112 patients with BC and 59 healthy controls were recruited into the present study. The expression level of serum miR‑103a‑3p was evaluated using reverse transcription‑quantitative PCR. Receiver operating characteristic curves were utilized to calculate diagnostic accuracy. Survival curves were generated to analyze survival outcomes. It was found that circulating miR‑103a‑3p level was upregulated in patients with BC compared with that in healthy controls, and its expression was decreased following surgery. In addition, miR‑103a‑3p expression level was also associated with advanced clinicopathological features, including positive epidermal growth factor receptor 2 status, metastasis and an advanced TNM stage. The circulating serum miR‑103a‑3p level could be used to discriminate between patients with BC and the healthy controls prior to surgery using an area under curve [(AUC), 0.697; 95% confidence intervals (CI), 0.615‑0.778], and distinguish patients with BC and metastasis from those without metastasis (AUC, 0.936; 95% CI, 0.892‑0.980). In addition, high expression level of miR‑103a‑3p was associated with worse survival outcomes in patients with BC. In conclusion, the present study suggests that miR‑103a‑3p could be a potential non‑invasive diagnostic and prognostic biomarker for BC.
View Figures
View References

Related Articles

Journal Cover

January-2022
Volume 23 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Liu H, Bian Q, Zhang W and Cui H: Circulating microRNA‑103a‑3p could be a diagnostic and prognostic biomarker for breast cancer. Oncol Lett 23: 38, 2022.
APA
Liu, H., Bian, Q., Zhang, W., & Cui, H. (2022). Circulating microRNA‑103a‑3p could be a diagnostic and prognostic biomarker for breast cancer. Oncology Letters, 23, 38. https://doi.org/10.3892/ol.2021.13156
MLA
Liu, H., Bian, Q., Zhang, W., Cui, H."Circulating microRNA‑103a‑3p could be a diagnostic and prognostic biomarker for breast cancer". Oncology Letters 23.1 (2022): 38.
Chicago
Liu, H., Bian, Q., Zhang, W., Cui, H."Circulating microRNA‑103a‑3p could be a diagnostic and prognostic biomarker for breast cancer". Oncology Letters 23, no. 1 (2022): 38. https://doi.org/10.3892/ol.2021.13156